By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Evotec today said that it has completed its acquisition of DeveloGen, a German biopharmaceutical discovery and development firm, in a deal worth up to €14 million ($17.9 million).

Hamburg, Germany-based Evotec inked the agreement to acquire DeveloGen in July. It said that as of closing of the deal, the sellers of 99.3 percent of DeveloGen's shares had transferred their shares to Evotec.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.